ADC Therapeutics SA (ADCT)

4,5700 +0,1600 (+3,63%) In data: 02:02PM EDT. Mercato aperto.

ADC Therapeutics SA

Biopôle
Route de la Corniche 3B
Epalinges 1066
Switzerland
41 21 653 02 00
https://www.adctherapeutics.com

Settore/i: Healthcare
Settore: Biotechnology
Impiegati a tempo pieno: 273

Figure dirigenziali chiave

Nome	Titolo	Retribuzione	Esercitate	Anno di nascita
Dr. Ameet Mallik M.B.A., M.S.	CEO & Director	1,84M	N/D	1973
Mr. Jose I. Carmona M.B.A.	Chief Financial Officer	884,86k	N/D	1972
Dr. Mohamed Zaki M.D., Ph.D.	Chief Medical Officer	2,41M	N/D	1965
Ms. Lisa Michelle Kallebo	Corporate Controller & Chief Accounting Officer	N/D	N/D	N/D
Dr. Michael Mulkerrin Ph.D.	Chief Technical Operations Officer	N/D	N/D	1955
Dr. Patrick van Berkel Ph.D.	Chief Scientific Officer	N/D	N/D	1968
Amanda Hamilton	Investor Relations Officer	N/D	N/D	N/D
Mr. Peter J. Graham Esq.	Chief Legal Officer	N/D	N/D	1967
Ms. Eugenia Litz	Vice President of Investor Relations & Corporate Communications	N/D	N/D	N/D
Ms. Kimberly Pope	Senior VP & Chief People Officer	N/D	N/D	1967

Gli importi risalgono al giorno 31 dicembre 2023 e i valori di compensazione riguardano l'anno fiscale che si chiude a tale data. La retribuzione include salari, bonus ecc. "Esercitate" è il valore delle opzioni esercitate durante l'anno fiscale. Valuta in USD.

Descrizione

ADC Therapeutics SA focuses on advancing its proprietary antibody drug conjugate (ADC) technology platform to transform the treatment paradigm for patients with hematologic malignancies and solid tumors. Its flagship product is ZYNLONTA, a CD19-directed ADC, received accelerated approval from the U.S. Food and Drug Administration and conditional approval from the European Commission for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy. The company is also seeking to continue expanding ZYNLONTA into international markets and into earlier lines of DLBCL and indolent lymphomas, including follicular lymphoma (FL) and marginal zone lymphoma (MZL) as a single agent and in combination through its LOTIS-5 confirmatory Phase 3 clinical trial and LOTIS-7 Phase 1b clinical trial, as well as through investigator-initiated trials (IITs). In addition, it is investigating a CD-22 targeted compound, ADCT-602 that is in a Phase 1/2 investigator-initiated study in relapsed or refractory B-cell acute lymphoblastic leukemia. Further, its clinical-stage pipeline consists of ADCT-601 (mipasetamab uzoptirine) targeting AXL as a single agent and/or in combination in sarcoma, pancreatic, and NSCLC, as well as pre-clinical stage pipeline includes a portfolio of next generation investigational ADCs targeting Claudin-6, NaPi2b, PSMA, and other undisclosed targets. The company was incorporated in 2011 and is headquartered in Epalinges, Switzerland.

Governance aziendale

L'ISS Governance QualityScore di ADC Therapeutics SA al N/D è N/D. I criteri di valutazione fondamentali sono revisione: N/D; Consiglio di Amministrazione: N/D; diritti degli azionisti: N/D; retribuzione: N/D.

Punteggi di corporate governance forniti da Institutional Shareholder Services (ISS). I punteggi indicano il rango decile relativo all’indice o alla regione. Un punteggio di decile pari a 1 indica un governance risk più basso, mentre un punteggio di 10 indica un governance risk più alto.